FindTrial
Sign In

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00251550
Enrollment
12
Registered
2005-11-10
Start date
2005-10-31
Completion date
2006-08-31
Last updated
2007-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pleural Mesotherioma

Brief summary

To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.

Interventions

DRUGPemetrexed
DRUGCisplatin

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Inapplicable for radical operation * Not received prior systemic chemotherapy * Performance status: 0-1

Exclusion criteria

* Having a history of sensitivity to platinum agent, folic acid or vitamin B12

Design outcomes

Primary

MeasureTime frame
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate—

Secondary

MeasureTime frame
Progression free survival—
Median survival time—
1 year survival rate—
Duration of response—
QOL—
Safety—
Plasma concentration—
Pulmonary function—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026